Treatment of metastatic TFE3 microphthalmia transcription factor translocation renal cell carcinoma: a case report.

ABSTRACT:

Background

Microphthalmia-associated transcription factor/transcription factor E (MiTF/TFE) translocation renal cell carcinoma (RCC) is a rare type of non-clear cell RCC (nccRCC), which is more common in females. Currently, there is no standardized treatment for advanced metastatic microphthalmia translocation RCC (MiT-RCC). The main treatment modalities include surgery, chemotherapy, immunotherapy, anti-vascular endothelial growth factor or vascular endothelial growth factor receptor (VEGFR) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and targeted therapy against the mesenchymal-epithelial transition (MET) factor signaling pathway.

Case description

We present the case of an 8-year-old male patient with hematuria and paroxysmal urinary pain. Based on tumor g

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC10998990 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature